Asston Pharmaceuticals IPO allotment today: Here's how to check status and latest GMP

The allotment status for Asston Pharmaceuticals Limited's Initial Public Offering (IPO) is set to be finalised today, marking a critical step for investors eagerly awaiting their share allocation. With high investor interest and a strong grey market premium (GMP), the IPO has created a buzz across the pharmaceutical and broader mid-cap segments.

IPO Snapshot

Asston Pharmaceuticals launched its IPO from July 9 to July 11, offering a mix of fresh issue and offer for sale (OFS) to raise approximately ₹500 crore. The price band was fixed at ₹152 to ₹160 per share, and the minimum lot size for retail investors was 93 shares, amounting to ₹14,880 per lot at the upper price band.

The company aims to utilise the proceeds from the IPO to expand its production capacity, enhance R&D capabilities, and reduce outstanding borrowings.

How to Check Asston Pharma IPO Allotment Status

Investors who subscribed to the IPO can check their allotment status through the following platforms:

1. Registrar Website (KFin Technologies Ltd.)

• Visit https://ris.kfintech.com/ipostatus

• Select ‘Asston Pharmaceuticals Limited’ from the drop-down menu.

• Enter either PAN, application number, or DP/Client ID.

• Click on ‘Search’ to view the allotment status.

2. BSE Website

• Go to https://www.bseindia.com/investors/appli_check.aspx

• Select 'Equity' and then the issue name.

• Enter the application number and PAN.

• Verify and click on ‘Search’ to see the status.

Successful applicants will see the number of shares allotted, while others may receive a message stating ‘No records found’ if not allotted.

Grey Market Premium (GMP) Trends

As of July 14, the grey market premium (GMP) for Asston Pharmaceuticals is trending at around ₹65–₹70 per share, indicating strong investor sentiment. This translates to a listing price expectation of ₹225–₹230, implying a potential gain of over 40% from the upper issue price.

"High GMP is reflective of investor confidence, particularly in a sector that has shown resilience and strong earnings growth post-pandemic," said Rajesh Jain, Senior Research Analyst at Reliant Broking.

Market Context and Subscription Details

The IPO witnessed robust demand across all investor categories:

• Qualified Institutional Buyers (QIBs): Subscribed 18.6 times

• Non-Institutional Investors (NIIs): Subscribed 29.4 times

• Retail Investors: Subscribed 11.3 times

• Overall Subscription: A whopping 21.7 times

Such oversubscription figures indicate that the IPO was well-received across institutional and retail segments, driven by the company's strong financials, scalable business model, and increasing relevance in the export-oriented pharma space.

Company Overview: Why the Buzz?

Founded in 2001, Asston Pharmaceuticals is a mid-sized pharma firm engaged in the development, manufacturing, and export of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company serves clients across 45 countries, including key markets like the US, EU, and South-East Asia.

Its revenue for FY24 stood at ₹1,285 crore, up from ₹1,010 crore in FY23, registering a 27% year-on-year growth. Net profit surged to ₹178 crore in FY24 from ₹132 crore in the previous fiscal.

The company operates five USFDA-approved plants and has consistently reinvested in research and regulatory compliance, a strategy that has earned it a premium valuation compared to peers.

Expert View: Is Listing Gain on the Cards?

According to Meera Shah, Vice President at JM Financial Services, “The combination of strong subscription numbers and healthy GMP suggests a favourable listing. However, mid-cap pharma stocks can be volatile post-listing, so profit-booking could come in early."

She adds, “Investors with a medium- to long-term view may benefit more, considering the company’s expansion pipeline and consistent EBITDA margin above 20%.”

What Next: Listing Date and Refunds

Following today’s allotment finalisation, the refund process for unallocated applicants will begin on July 15, while shares will be credited to Demat accounts by July 16.

Asston Pharmaceuticals is expected to debut on the stock exchanges (BSE and NSE) on Thursday, July 17, 2025.

Investor Outlook: Should You Hold or Exit?

For those allotted shares, the big decision will be whether to book listing gains or hold for potential long-term upside.

• Short-term traders may find the 40% GMP-backed premium attractive for listing-day exit.

• Long-term investors, however, may benefit from holding, especially given the company’s upcoming capacity expansion and entry into newer therapeutic segments such as oncology and biologics.

“Pharma stocks have shown defensive traits amid macro uncertainty,” said Anil Goyal, Director at CapVal Research. “Asston’s strong export orientation and regulatory compliance make it a viable pick for long-term portfolios.”

Asston Pharmaceuticals' IPO allotment is being closely watched due to its stellar oversubscription and encouraging GMP trends. While listing gains seem likely, long-term performance will hinge on the company’s ability to deliver on its growth promises in the competitive pharmaceutical space.